Skip to content

Study · Animal study (in vivo) · rat · 1993

4 results

MIF-1 fails to modify agonist-induced oral activity in neonatal 6-OHDA-treated rats.

Gong L, Kostrzewa RM, Kalbfleisch JH

Peptides1 Nov 1993Cited by 6 (Europe PMC)

PMID7907787 (opens in a new tab)DOI10.1016/0196-9781(93)90170-l (opens in a new tab)PepBankPUB-07907787
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Activity measurement

    In intact and neonatal 6-OHDA-treated rats, acute MIF‑1 did not modify SKF 38393-induced oral activity.

    In plain wordsIn intact and brain-lesioned rats, MIF‑1 did not change oral activity caused by SKF 38393.

    Peptide
    MIF-1 (Pro-Leu-Gly-NH2)
    Outcome
    No significant changeAcute SKF 38393-induced oral activity
    Study

    ratn: not reported in source

    Intact and neonatal 6-OHDA-treated adult rats
    Comparator
    Agonist response without MIF-1
    Outcome group
    Receptor activity and mechanism · Nervous system and cognition
    Studied dose
    0.1, 1.0, or 10.0 mg/kg · intraperitonealAs given in this study (rat).

    Source sentences

    Summary
    Although both agonists increased oral activity in control and neonatal 6-OHDA-treated rats, MIF-1 did not modify the response.
    2 context sentences
    Summary · context
    To test whether MIF-1 would affect dopamine (DA) agonist-induced and serotonin (5-HT) agonist-induced oral activity, both intact and neonatal 6-OHDA-treated rats were studied.
    Summary · context
    At approximately 6 months rats were treated with MIF-1 (0.1, 1.0, or 10.0 mg/kg, IP), 10 min before SKF 38393 HCl (1.0 mg/kg, IP) or m-chlorophenylpiperazine 2HCl (m-CPP 2HCl; 0.5 mg/kg, IP), DA D1 and 5-HT1C,2 receptor agonists, respectively.
  2. 02AnimalAnimal study (in vivo)Activity measurement

    In intact and neonatal 6-OHDA-treated rats, acute MIF‑1 did not modify m-CPP-induced oral activity.

    In plain wordsIn intact and brain-lesioned rats, MIF‑1 did not change oral activity caused by m-CPP.

    Peptide
    MIF-1 (Pro-Leu-Gly-NH2)
    Outcome
    No significant changeAcute m-CPP-induced oral activity
    Study

    ratn: not reported in source

    Intact and neonatal 6-OHDA-treated adult rats
    Comparator
    Agonist response without MIF-1
    Outcome group
    Receptor activity and mechanism · Nervous system and cognition
    Studied dose
    0.1, 1.0, or 10.0 mg/kg · intraperitonealAs given in this study (rat).

    Source sentences

    Summary
    Although both agonists increased oral activity in control and neonatal 6-OHDA-treated rats, MIF-1 did not modify the response.
    2 context sentences
    Summary · context
    To test whether MIF-1 would affect dopamine (DA) agonist-induced and serotonin (5-HT) agonist-induced oral activity, both intact and neonatal 6-OHDA-treated rats were studied.
    Summary · context
    At approximately 6 months rats were treated with MIF-1 (0.1, 1.0, or 10.0 mg/kg, IP), 10 min before SKF 38393 HCl (1.0 mg/kg, IP) or m-chlorophenylpiperazine 2HCl (m-CPP 2HCl; 0.5 mg/kg, IP), DA D1 and 5-HT1C,2 receptor agonists, respectively.
  3. 03AnimalAnimal study (in vivo)Activity measurement

    In intact and neonatal 6-OHDA-treated rats, repeated MIF‑1 did not modify SKF 38393-induced oral activity.

    In plain wordsIn intact and brain-lesioned rats, repeated MIF‑1 did not change oral activity caused by SKF 38393.

    Peptide
    MIF-1 (Pro-Leu-Gly-NH2)
    Outcome
    No significant changeRepeated-dose SKF 38393-induced oral activity
    Study

    ratn: not reported in source

    Intact and neonatal 6-OHDA-treated adult rats
    Comparator
    Agonist response without MIF-1
    Outcome group
    Receptor activity and mechanism · Nervous system and cognition
    Studied dose
    0.1, 1.0, or 10.0 mg/kg · intraperitoneal · 21 consecutive daysAs given in this study (rat).

    Source sentences

    Summary
    In rats that received either of the three doses of MIF-1 for 21 consecutive days, there was still no observed effect of MIF-1 on the oral response of control and 6-OHDA-lesioned rats to SKF 38393 and m-CPP.
    2 context sentences
    Summary · context
    To test whether MIF-1 would affect dopamine (DA) agonist-induced and serotonin (5-HT) agonist-induced oral activity, both intact and neonatal 6-OHDA-treated rats were studied.
    Summary · context
    At approximately 6 months rats were treated with MIF-1 (0.1, 1.0, or 10.0 mg/kg, IP), 10 min before SKF 38393 HCl (1.0 mg/kg, IP) or m-chlorophenylpiperazine 2HCl (m-CPP 2HCl; 0.5 mg/kg, IP), DA D1 and 5-HT1C,2 receptor agonists, respectively.
  4. 04AnimalAnimal study (in vivo)Activity measurement

    In intact and neonatal 6-OHDA-treated rats, repeated MIF‑1 did not modify m-CPP-induced oral activity.

    In plain wordsIn intact and brain-lesioned rats, repeated MIF‑1 did not change oral activity caused by m-CPP.

    Peptide
    MIF-1 (Pro-Leu-Gly-NH2)
    Outcome
    No significant changeRepeated-dose m-CPP-induced oral activity
    Study

    ratn: not reported in source

    Intact and neonatal 6-OHDA-treated adult rats
    Comparator
    Agonist response without MIF-1
    Outcome group
    Receptor activity and mechanism · Nervous system and cognition
    Studied dose
    0.1, 1.0, or 10.0 mg/kg · intraperitoneal · 21 consecutive daysAs given in this study (rat).

    Source sentences

    Summary
    In rats that received either of the three doses of MIF-1 for 21 consecutive days, there was still no observed effect of MIF-1 on the oral response of control and 6-OHDA-lesioned rats to SKF 38393 and m-CPP.
    2 context sentences
    Summary · context
    To test whether MIF-1 would affect dopamine (DA) agonist-induced and serotonin (5-HT) agonist-induced oral activity, both intact and neonatal 6-OHDA-treated rats were studied.
    Summary · context
    At approximately 6 months rats were treated with MIF-1 (0.1, 1.0, or 10.0 mg/kg, IP), 10 min before SKF 38393 HCl (1.0 mg/kg, IP) or m-chlorophenylpiperazine 2HCl (m-CPP 2HCl; 0.5 mg/kg, IP), DA D1 and 5-HT1C,2 receptor agonists, respectively.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.